HYTERA
17.3.2022 08:37:06 CET | Business Wire | Press release
Technology underpins the successful running of all kinds of mega events. Audiences these days are constantly amazed by the top-notch technologies adopted by the Beijing 2022 Winter Olympics and Paralympic Winter Games. Among them, the professional mobile radios (PMR), which support critical communications of the world-class event, have earned wide attention from the public.
As one of the key communication solution suppliers of Beijing 2022 Winter Olympic and Paralympic Winter Games, Hytera provided a certain amount of TETRA devices, PMR-LTE convergent solutions and command & control systems to the security officers and rescue teams during the races. Hytera’s communication technologies also played a major role in the execution of COVID-19 prevention in the Olympic Village.
In fact, besides the global mega sport events, Hytera’s products and solutions are also chosen by industry clients across public safety, transportation, manufacturing, oil and gas as well as the retail and hospitality industries.
Innovation Is in Hytera’s DNA
With continuous investment in technology innovation, Hytera is committed to promoting open communication standards from narrowband to broadband, including TETRA, DMR, PDT and LTE with independent intellectual property rights, which makes it a leading provider of professional communication solutions.
Hytera recently added the H Series to its DMR product portfolios. The new series is built from the ground up on an entirely new technology platform. It is the first of its kind in the industry when it comes to functionality, user experience, and ruggedness, providing efficient and reliable communications to users in security, education industry and customer service roles as well as those working in severe working conditions.
Global Recognition and Partnership Achieved by Hytera
To meet the growing needs of business and critical communication users, Hytera innovatively developed a variety of products and technology solutions. Among them, there are DMR terminals, TETRA terminals, PoC Radios, multimode advanced radios, body worn cameras, command & dispatch and emergency response software that have contributed to the success of users working in the vertical industries, such as public safety, energy, transportation, utility, commercial and operator markets. With audio, visual and data capabilities, Hytera has provided faster, safer, and more versatile connectivity options.
Hytera has showcased its technological strength and achieved global recognition and partnerships. The International Critical Communications Awards (ICAA) awarded Hytera the “Best New LTE or Hybrid Device” for its LTE & TETRA convergent device PTC760, as well as the “Best Use of Critical Communications in Utilities” in recognition of its Hytalk PoC solution for Turkey Electricity Company.
Global partnerships have also validated Hytera’s competence. Hytera played a role in the 2021 FIFA Arab Cup and the 2018 FIFA World Cup with its local partners. Hytera also worked with the security department in Tajikistan during the SCO Summit 2021.
Supporting Communities under Global Challenges
While succeeding in landing international business partnerships, Hytera has also contributed its capacities to tackle global challenges.
To deal with the outbreak of the COVID-19 pandemic, Hytera has actively contributed its capabilities to improve disease prevention. Hytera’s two way radios and pandemic prevention solutions provided fast and reliable non-contact communication to the workers from hospitals, enterprises and security departments around the world to fight against the virus.
As a key player in the critical communications industry, Hytera, empowered by top-performing technologies, will continue to support industrial users, and ensure safer and stronger communication networks worldwide.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220316006155/en/
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press release
- Vertex is on track for the U.S. FDA Prescription Drug User Fee Act (PDUFA) date of November 30 for potential accelerated approval of povetacicept –- Data published in NEJM and presented at ASN highlight povetacicept’s unique trifecta of efficacy, favorable safety, and the simplicity of dosing at-home every 4 weeks with a low-volume autoinjector –- Data presented at ASN include a qualitative study examining patient perspectives on current and emerging IgAN therapies, showing that 96% of participants preferred an autoinjector over a prefilled syringe, and 80% of participants preferred dosing every 4 weeks versus weekly dosing - - New clinical studies of povetacicept underway including a study evaluating patient experience on povetacicept administered via autoinjector - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Soc
BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press release
New data from HERIZON-GEA-01 Phase 3 trial show 36-month overall survival of nearly 40% with TEVIMBRA plus ZIIHERA and chemotherapy, and median OS reaching 27 monthsTEVIMBRA-containing arm was associated with a four-month longer median OS compared with ZIIHERA plus chemotherapy BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne,
Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:10:00 CEST | Press release
Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com
inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press release
Collaboration will establish the roadmap for bringing Pony.ai robotaxis to Kazakhstan on the inDrive ride-hailing platform, leveraging the NVIDIA Hyperion and the NVIDIA Halos safety system. inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a lea
Brenus Pharma's Novel In Vivo Immunotherapy STC-1010 Shows Safety, Activating T Cells in First-Line MSS Metastatic Colorectal Cancers With 2 Complete Responses.23.10.2026 14:50:00 CEST | Press release
Phase Ia BreAK CRC-001 at ESMO 2026: 43% of patients, all initially unresectable, became eligible for surgery Poster 1023P – Developmental Therapeutics Brenus Pharma, a clinical-stage biotech company, announced first data from the Phase Ia dose escalation of BreAK CRC-001. Nine unresectable patients were treated; 89% had liver metastases and 89% KRAS-mutant tumors, a population refractory to immunotherapy. Median follow-up: 8 months (1–14; data cut-off 6/08/2026). 95% of metastatic colorectal cancers are pMMR/MSS tumors, poorly immunogenic and resistant to immunotherapy. STC-1010, the company’s lead in vivo DC-engager, is designed to make these “cold” tumors visible to immune cells. Safety: no dose-limiting toxicity, only grade 1–2 related adverse events. Clinical activity (seven evaluable patients, RECIST 1.1): 100% disease control, 57% objective response rate (4/7). 43% of patients became operable (3/7): two with no evidence of disease afterward. Molecular profile: ctDNA dropped by u
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
